{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T01:50:08Z","timestamp":1794707408561,"version":"4.9.1"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T00:00:00Z","timestamp":1764806400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T00:00:00Z","timestamp":1764806400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["GeroScience"],"DOI":"10.1007\/s11357-025-02026-5","type":"journal-article","created":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T22:16:25Z","timestamp":1764886585000},"page":"6871-6885","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Multimorbidity, frailty and polypharmacy in European and Asian patients with atrial fibrillation: a comparison of two regional prospective observational registries"],"prefix":"10.1007","volume":"48","author":[{"given":"Davide Antonio","family":"Mei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Proietti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulio Francesco","family":"Romiti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommaso","family":"Bucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernadette","family":"Corica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alena","family":"Shantsila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hung-Fat","family":"Tse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Boriani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tze-Fan","family":"Chao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7566-1626","authenticated-orcid":false,"given":"Gregory Y. H.","family":"Lip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,4]]},"reference":[{"key":"2026_CR1","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/euae195","author":"S Cheng","year":"2024","unstructured":"Cheng S, He J, Han Y, et al. Global burden of atrial fibrillation\/atrial flutter and its attributable risk factors from 1990 to 2021. Europace. 2024. https:\/\/doi.org\/10.1093\/europace\/euae195.","journal-title":"Europace"},{"key":"2026_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2022.100386","volume":"17","author":"J Wu","year":"2022","unstructured":"Wu J, Nadarajah R, Nakao YM, et al. Temporal trends and patterns in atrial fibrillation incidence: a population-based study of 3\u00b74 million individuals. The Lancet Regional Health - Europe. 2022;17:100386. https:\/\/doi.org\/10.1016\/j.lanepe.2022.100386.","journal-title":"The Lancet Regional Health - Europe"},{"key":"2026_CR3","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/euae070","author":"D Linz","year":"2024","unstructured":"Linz D, Andrade JG, Arbelo E, et al. Longer and better lives for patients with atrial fibrillation: the 9th AFNET\/EHRA consensus conference. Europace. 2024. https:\/\/doi.org\/10.1093\/europace\/euae070.","journal-title":"Europace"},{"issue":"3","key":"2026_CR4","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.115.002197","volume":"5","author":"SD Pokorney","year":"2016","unstructured":"Pokorney SD, Piccini JP, Stevens SR, et al. Cause of death and predictors of all-cause mortality in anticoagulated patients with nonvalvular atrial fibrillation: data from ROCKET AF. J Am Heart Assoc. 2016;5(3):e002197. https:\/\/doi.org\/10.1161\/JAHA.115.002197.","journal-title":"J Am Heart Assoc"},{"key":"2026_CR5","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2025.1337","author":"JJ McCabe","year":"2025","unstructured":"McCabe JJ, Cheung Y, Foley M, et al. Residual risk of recurrent stroke despite anticoagulation in patients with atrial fibrillation: a systematic review and meta-analysis. JAMA Neurol. 2025. https:\/\/doi.org\/10.1001\/jamaneurol.2025.1337.","journal-title":"JAMA Neurol"},{"issue":"3","key":"2026_CR6","doi-asserted-by":"publisher","DOI":"10.1111\/eci.14371","volume":"55","author":"Y Liu","year":"2025","unstructured":"Liu Y, Chen Y, Olier I, et al. Residual risk prediction in anticoagulated patients with atrial fibrillation using machine learning: a report from the GLORIA-AF registry phase II\/III. Eur J Clin Invest. 2025;55(3):e14371. https:\/\/doi.org\/10.1111\/eci.14371.","journal-title":"Eur J Clin Invest"},{"issue":"42","key":"2026_CR7","doi-asserted-by":"publisher","first-page":"4422","DOI":"10.1093\/eurheartj\/ehad571","volume":"44","author":"J Wu","year":"2023","unstructured":"Wu J, Nadarajah R, Nakao YM, et al. Temporal trends of cause-specific mortality after diagnosis of atrial fibrillation. Eur Heart J. 2023;44(42):4422\u201331. https:\/\/doi.org\/10.1093\/eurheartj\/ehad571.","journal-title":"Eur Heart J"},{"issue":"10","key":"2026_CR8","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1055\/a-2325-5923","volume":"124","author":"Y Wang","year":"2024","unstructured":"Wang Y, Guo Y, Qin M, et al. 2024 Chinese Expert Consensus Guidelines on the Diagnosis and Treatment of Atrial Fibrillation in the Elderly, Endorsed by Geriatric Society of Chinese Medical Association (Cardiovascular Group) and Chinese Society of Geriatric Health Medicine (Cardiovascular Branch): executive summary. Thromb Haemost. 2024;124(10):897\u2013911. https:\/\/doi.org\/10.1055\/a-2325-5923.","journal-title":"Thromb Haemost"},{"issue":"12","key":"2026_CR9","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1055\/a-2434-9244","volume":"124","author":"T Potpara","year":"2024","unstructured":"Potpara T, Romiti GF, Sohns C. The 2024 European Society of Cardiology guidelines for diagnosis and management of atrial fibrillation: a viewpoint from a practicing clinician\u2019s perspective. Thromb Haemost. 2024;124(12):1087\u201394. https:\/\/doi.org\/10.1055\/a-2434-9244.","journal-title":"Thromb Haemost"},{"key":"2026_CR10","doi-asserted-by":"publisher","unstructured":"Romiti GF, Corica B, Mei DA, et al. Association of comorbidity patterns with outcomes and relation with the ABC pathway effectiveness in European patients with atrial fibrillation. Heart Rhythm. 2025. https:\/\/doi.org\/10.1016\/j.hrthm.2025.02.049","DOI":"10.1016\/j.hrthm.2025.02.049"},{"issue":"1","key":"2026_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-024-03373-4","volume":"22","author":"GF Romiti","year":"2024","unstructured":"Romiti GF, Corica B, Mei DA, et al. Patterns of comorbidities in patients with atrial fibrillation and impact on management and long-term prognosis: an analysis from the prospective global GLORIA-AF registry. BMC Med. 2024;22(1):151. https:\/\/doi.org\/10.1186\/s12916-024-03373-4.","journal-title":"BMC Med"},{"issue":"4","key":"2026_CR12","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1093\/europace\/euac123","volume":"25","author":"I Savelieva","year":"2023","unstructured":"Savelieva I, Fumagalli S, Kenny RA, et al. EHRA expert consensus document on the management of arrhythmias in frailty syndrome, endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA). Europace. 2023;25(4):1249\u201376. https:\/\/doi.org\/10.1093\/europace\/euac123.","journal-title":"Europace"},{"key":"2026_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.exger.2021.111482","volume":"153","author":"M Proietti","year":"2021","unstructured":"Proietti M, Esteve-Pastor MA, Rivera-Caravaca JM, et al. Relationship between multimorbidity and outcomes in atrial fibrillation. Exp Gerontol. 2021;153:111482. https:\/\/doi.org\/10.1016\/j.exger.2021.111482.","journal-title":"Exp Gerontol"},{"key":"2026_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2022.101652","volume":"79","author":"M Proietti","year":"2022","unstructured":"Proietti M, Romiti GF, Raparelli V, et al. Frailty prevalence and impact on outcomes in patients with atrial fibrillation: a systematic review and meta-analysis of 1,187,000 patients. Ageing Res Rev. 2022;79:101652. https:\/\/doi.org\/10.1016\/j.arr.2022.101652.","journal-title":"Ageing Res Rev"},{"issue":"5","key":"2026_CR15","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1007\/s00392-015-0936-y","volume":"105","author":"M Proietti","year":"2016","unstructured":"Proietti M, Raparelli V, Olshansky B, Lip GY. Polypharmacy and major adverse events in atrial fibrillation: observations from the AFFIRM trial. Clin Res Cardiol. 2016;105(5):412\u201320. https:\/\/doi.org\/10.1007\/s00392-015-0936-y.","journal-title":"Clin Res Cardiol"},{"issue":"1","key":"2026_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-024-03792-3","volume":"22","author":"DA Mei","year":"2024","unstructured":"Mei DA, Romiti GF, Bucci T, et al. Peripheral artery disease, antithrombotic treatment and outcomes in European and Asian patients with atrial fibrillation: analysis from two prospective observational registries. BMC Med. 2024;22(1):567. https:\/\/doi.org\/10.1186\/s12916-024-03792-3.","journal-title":"BMC Med"},{"key":"2026_CR17","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/eux301","author":"G Boriani","year":"2017","unstructured":"Boriani G, Proietti M, Laroche C, et al. Contemporary stroke prevention strategies in 11 096 European patients with atrial fibrillation: a report from the EURObservational Research Programme on Atrial Fibrillation (EORP-AF) long-term general registry. EP Europace. 2017. https:\/\/doi.org\/10.1093\/europace\/eux301.","journal-title":"EP Europace"},{"issue":"12","key":"2026_CR18","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1093\/europace\/euab327","volume":"24","author":"HF Tse","year":"2022","unstructured":"Tse HF, Teo WS, Siu CW, et al. Prognosis and treatment of atrial fibrillation in Asian cities: 1-year review of the Asia-Pacific Heart Rhythm Society Atrial Fibrillation Registry. Europace. 2022;24(12):1889\u201398. https:\/\/doi.org\/10.1093\/europace\/euab327.","journal-title":"Europace"},{"key":"2026_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2024.100967","author":"K Teppo","year":"2024","unstructured":"Teppo K, Lip GYH, Airaksinen KEJ, et al. Comparing CHA2DS2-VA and CHA2DS2-VASc scores for stroke risk stratification in patients with atrial fibrillation: a temporal trends analysis from the retrospective Finnish AntiCoagulation in Atrial Fibrillation (FinACAF) cohort. The Lancet Regional Health \u2013 Europe. 2024. https:\/\/doi.org\/10.1016\/j.lanepe.2024.100967.","journal-title":"The Lancet Regional Health \u2013 Europe"},{"key":"2026_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.hrthm.2025.05.067","author":"WH Cheng","year":"2025","unstructured":"Cheng WH, Chan YH, Kuo L, et al. Stroke risks in women vs men in Asian patients with atrial fibrillation: a temporal trend analysis and a comparison of the CHA2DS2-VASc and CHA2DS2-VA stroke risk stratification scores. Heart Rhythm. 2025. https:\/\/doi.org\/10.1016\/j.hrthm.2025.05.067.","journal-title":"Heart Rhythm"},{"issue":"5","key":"2026_CR21","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1378\/chest.10-0134","volume":"2010","author":"R Pisters","year":"2010","unstructured":"Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJGM, Lip GYH. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation. Chest. 2010;2010(5):1093\u2013100. https:\/\/doi.org\/10.1378\/chest.10-0134.","journal-title":"Chest"},{"issue":"1","key":"2026_CR22","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1093\/eurpub\/cky098","volume":"29","author":"MC Johnston","year":"2019","unstructured":"Johnston MC, Crilly M, Black C, Prescott GJ, Mercer SW. Defining and measuring multimorbidity: a systematic review of systematic reviews. Eur J Public Health. 2019;29(1):182\u20139. https:\/\/doi.org\/10.1093\/eurpub\/cky098.","journal-title":"Eur J Public Health"},{"key":"2026_CR23","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/afac192","author":"M Proietti","year":"2022","unstructured":"Proietti M, Romiti GF, Vitolo M, et al. Epidemiology and impact of frailty in patients with atrial fibrillation in Europe. Age Ageing. 2022. https:\/\/doi.org\/10.1093\/ageing\/afac192.","journal-title":"Age Ageing"},{"issue":"7","key":"2026_CR24","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1093\/gerona\/62.7.722","volume":"62","author":"K Rockwood","year":"2007","unstructured":"Rockwood K, Mitnitski A. Frailty in relation to the accumulation of deficits. J Gerontol A Biol Sci Med Sci. 2007;62(7):722\u20137. https:\/\/doi.org\/10.1093\/gerona\/62.7.722.","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"2026_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2318-8-24","volume":"8","author":"SD Searle","year":"2008","unstructured":"Searle SD, Mitnitski A, Gahbauer EA, Gill TM, Rockwood K. A standard procedure for creating a frailty index. BMC Geriatr. 2008;8:24. https:\/\/doi.org\/10.1186\/1471-2318-8-24.","journal-title":"BMC Geriatr"},{"issue":"1","key":"2026_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s12877-017-0621-2","volume":"17","author":"N Masnoon","year":"2017","unstructured":"Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. What is polypharmacy? A systematic review of definitions. BMC Geriatr. 2017;17(1):230. https:\/\/doi.org\/10.1186\/s12877-017-0621-2.","journal-title":"BMC Geriatr"},{"issue":"12","key":"2026_CR27","doi-asserted-by":"publisher","first-page":"2030","DOI":"10.1055\/s-0042-1756355","volume":"122","author":"GF Romiti","year":"2022","unstructured":"Romiti GF, Proietti M, Bonini N, et al. Clinical complexity domains, anticoagulation, and outcomes in patients with atrial fibrillation: a report from the GLORIA-AF registry phase II and III. Thromb Haemost. 2022;122(12):2030\u201341. https:\/\/doi.org\/10.1055\/s-0042-1756355.","journal-title":"Thromb Haemost"},{"issue":"8","key":"2026_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2023.101752","volume":"48","author":"M Proietti","year":"2023","unstructured":"Proietti M, Romiti GF, Corica B, et al. Features of clinical complexity in European patients with atrial fibrillation: a report from a European observational prospective AF registry. Curr Probl Cardiol. 2023;48(8):101752. https:\/\/doi.org\/10.1016\/j.cpcardiol.2023.101752.","journal-title":"Curr Probl Cardiol"},{"issue":"20","key":"2026_CR29","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.030565","volume":"12","author":"GF Romiti","year":"2023","unstructured":"Romiti GF, Proietti M, Corica B, et al. Implications of clinical risk phenotypes on the management and natural history of atrial fibrillation: a report from the GLORIA-AF. J Am Heart Assoc. 2023;12(20):e030565. https:\/\/doi.org\/10.1161\/JAHA.123.030565.","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"2026_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-022-02526-7","volume":"20","author":"GF Romiti","year":"2022","unstructured":"Romiti GF, Proietti M, Vitolo M, et al. Clinical complexity and impact of the ABC (Atrial fibrillation Better Care) pathway in patients with atrial fibrillation: a report from the ESC-EHRA EURObservational Research Programme in AF General Long-Term Registry. BMC Med. 2022;20(1):326. https:\/\/doi.org\/10.1186\/s12916-022-02526-7.","journal-title":"BMC Med"},{"issue":"2","key":"2026_CR31","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1055\/s-0043-1769735","volume":"124","author":"M Grymonprez","year":"2024","unstructured":"Grymonprez M, Petrovic M, De Backer TL, Steurbaut S, Lahousse L. The impact of polypharmacy on the effectiveness and safety of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Thromb Haemost. 2024;124(2):135\u201348. https:\/\/doi.org\/10.1055\/s-0043-1769735.","journal-title":"Thromb Haemost"},{"issue":"2","key":"2026_CR32","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1055\/s-0043-1770724","volume":"125","author":"Y Zheng","year":"2025","unstructured":"Zheng Y, Li S, Liu X, Lip GYH, Guo L, Zhu W. Effect of oral anticoagulants in atrial fibrillation patients with polypharmacy: a meta-analysis. Thromb Haemost. 2025;125(2):166\u201377. https:\/\/doi.org\/10.1055\/s-0043-1770724.","journal-title":"Thromb Haemost"},{"key":"2026_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.101860","volume":"57","author":"SR Chowdhury","year":"2023","unstructured":"Chowdhury SR, Chandra Das D, Sunna TC, Beyene J, Hossain A. Global and regional prevalence of multimorbidity in the adult population in community settings: a systematic review and meta-analysis. EClinicalMedicine. 2023;57:101860. https:\/\/doi.org\/10.1016\/j.eclinm.2023.101860.","journal-title":"EClinicalMedicine"},{"issue":"1","key":"2026_CR34","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1093\/ageing\/afaa219","volume":"50","author":"R O\u2019Caoimh","year":"2021","unstructured":"O\u2019Caoimh R, Sezgin D, O\u2019Donovan MR, et al. Prevalence of frailty in 62 countries across the world: a systematic review and meta-analysis of population-level studies. Age Ageing. 2021;50(1):96\u2013104. https:\/\/doi.org\/10.1093\/ageing\/afaa219.","journal-title":"Age Ageing"},{"key":"2026_CR35","doi-asserted-by":"publisher","first-page":"102039","DOI":"10.1016\/j.eclinm.2023.102039","volume":"63","author":"GF Romiti","year":"2023","unstructured":"Romiti GF, Corica B, Proietti M, et al. Patterns of oral anticoagulant use and outcomes in Asian patients with atrial fibrillation: a post-hoc analysis from the GLORIA-AF registry. EClinMed. 2023;63:102039. https:\/\/doi.org\/10.1016\/j.eclinm.2023.102039.","journal-title":"EClinMed"},{"key":"2026_CR36","doi-asserted-by":"publisher","DOI":"10.1136\/openhrt-2024-003109","author":"CY Cheng","year":"2025","unstructured":"Cheng CY, Lian TY, Zhu XJ, et al. Atrial fibrillation outcomes in patients from Asia and non-Asia countries: insights from GARFIELD-AF. Open Heart. 2025. https:\/\/doi.org\/10.1136\/openhrt-2024-003109.","journal-title":"Open Heart"},{"issue":"1","key":"2026_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-020-08929-6","volume":"20","author":"KB Son","year":"2020","unstructured":"Son KB. The speed of adoption of new drugs and prescription volume after the amendments in reimbursement coverage: the case of non-vitamin K antagonist oral anticoagulants in South Korea. BMC Public Health. 2020;20(1):797. https:\/\/doi.org\/10.1186\/s12889-020-08929-6.","journal-title":"BMC Public Health"},{"issue":"1","key":"2026_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/s12872-020-01330-6","volume":"20","author":"T Liu","year":"2020","unstructured":"Liu T, Yang HL, Gu L, et al. Current status and factors influencing oral anticoagulant therapy among patients with non-valvular atrial fibrillation in Jiangsu province, China: a multi-center, cross-sectional study. BMC Cardiovasc Disord. 2020;20(1):22. https:\/\/doi.org\/10.1186\/s12872-020-01330-6.","journal-title":"BMC Cardiovasc Disord"},{"issue":"8","key":"2026_CR39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003730","volume":"18","author":"J Zhao","year":"2021","unstructured":"Zhao J, Wang H, Li X, et al. Importance of attributes and willingness to pay for oral anticoagulant therapy in patients with atrial fibrillation in China: a discrete choice experiment. PLoS Med. 2021;18(8):e1003730. https:\/\/doi.org\/10.1371\/journal.pmed.1003730.","journal-title":"PLoS Med"},{"issue":"4","key":"2026_CR40","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.jacc.2007.01.098","volume":"50","author":"AY Shen","year":"2007","unstructured":"Shen AY, Yao JF, Brar SS, Jorgensen MB, Chen W. Racial\/ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation. J Am Coll Cardiol. 2007;50(4):309\u201315. https:\/\/doi.org\/10.1016\/j.jacc.2007.01.098.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"2026_CR41","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1093\/ageing\/afab024","volume":"50","author":"J Buck","year":"2021","unstructured":"Buck J, Fromings Hill J, Martin A, et al. Reasons for discontinuing oral anticoagulation therapy for atrial fibrillation: a systematic review. Age Ageing. 2021;50(4):1108\u201317. https:\/\/doi.org\/10.1093\/ageing\/afab024.","journal-title":"Age Ageing"},{"issue":"4","key":"2026_CR42","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1002\/joa3.12183","volume":"35","author":"HS Park","year":"2019","unstructured":"Park HS, Kim YH, Kim JS, et al. Status of international normalized ratio control and treatment patterns in patients with nonvalvular atrial fibrillation taking vitamin K antagonist with or without antiplatelet therapy: Results from KORAFII registry. J Arrhythm. 2019;35(4):593\u2013601. https:\/\/doi.org\/10.1002\/joa3.12183.","journal-title":"J Arrhythm"},{"issue":"6","key":"2026_CR43","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.joa.2015.04.004","volume":"31","author":"T Shiga","year":"2015","unstructured":"Shiga T, Naganuma M, Nagao T, et al. Persistence of non-vitamin K antagonist oral anticoagulant use in Japanese patients with atrial fibrillation: a single-center observational study. J Arrhythm. 2015;31(6):339\u201344. https:\/\/doi.org\/10.1016\/j.joa.2015.04.004.","journal-title":"J Arrhythm"},{"issue":"12","key":"2026_CR44","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.122.026844","volume":"12","author":"T Kondo","year":"2023","unstructured":"Kondo T, Adachi T, Kobayashi K, et al. Physical frailty and use of guideline-recommended drugs in patients with heart failure and reduced ejection fraction. J Am Heart Assoc. 2023;12(12):e026844. https:\/\/doi.org\/10.1161\/JAHA.122.026844.","journal-title":"J Am Heart Assoc"},{"key":"2026_CR45","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6963-13-238","volume":"13","author":"SB Meyer","year":"2013","unstructured":"Meyer SB, Luong TC, Mamerow L, Ward PR. Inequities in access to healthcare: analysis of national survey data across six Asia-Pacific countries. BMC Health Serv Res. 2013;13:238. https:\/\/doi.org\/10.1186\/1472-6963-13-238.","journal-title":"BMC Health Serv Res"},{"key":"2026_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.lansea.2025.100549","volume":"34","author":"R Krittayaphong","year":"2025","unstructured":"Krittayaphong R, Kaolawanich Y, Phrommintikul A, et al. The burden of atrial fibrillation and unmet needs of its management in Southeast Asia and South Asia. The Lancet Regional Health - Southeast Asia. 2025;34:100549. https:\/\/doi.org\/10.1016\/j.lansea.2025.100549.","journal-title":"The Lancet Regional Health - Southeast Asia"},{"issue":"12","key":"2026_CR47","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.40071","volume":"4","author":"Y Yao","year":"2021","unstructured":"Yao Y, Guo Y, Lip GYH. The effects of implementing a mobile health-technology supported pathway on atrial fibrillation-related adverse events among patients with multimorbidity: the mAFA-II randomized clinical trial. JAMA Netw Open. 2021;4(12):e2140071. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.40071.","journal-title":"JAMA Netw Open"},{"key":"2026_CR48","doi-asserted-by":"publisher","DOI":"10.1055\/s-0041-1739411","author":"TF Chao","year":"2022","unstructured":"Chao TF, Joung B, Takahashi Y, et al. 2021 focused update consensus guidelines of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation: executive summary. Thromb Haemost. 2022. https:\/\/doi.org\/10.1055\/s-0041-1739411.","journal-title":"Thromb Haemost"},{"key":"2026_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacasi.2023.04.008","author":"T Bucci","year":"2023","unstructured":"Bucci T, Proietti M, Shantsila A, et al. Integrated care for atrial fibrillation using the ABC pathway in the prospective APHRS-AF registry. JACC Asia. 2023. https:\/\/doi.org\/10.1016\/j.jacasi.2023.04.008.","journal-title":"JACC Asia"},{"key":"2026_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2020.01.052","author":"Y Guo","year":"2020","unstructured":"Guo Y, Lane DA, Wang L, et al. Mobile health technology to improve care for patients with atrial fibrillation. J Am Coll Cardiol. 2020. https:\/\/doi.org\/10.1016\/j.jacc.2020.01.052.","journal-title":"J Am Coll Cardiol"},{"key":"2026_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03511-2","author":"M Chu","year":"2025","unstructured":"Chu M, Zhang S, Gong J, et al. Telemedicine-based integrated management of atrial fibrillation in village clinics: a cluster randomized trial. Nat Med. 2025. https:\/\/doi.org\/10.1038\/s41591-025-03511-2.","journal-title":"Nat Med"},{"key":"2026_CR52","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-024-09037-6","author":"B Corica","year":"2024","unstructured":"Corica B, Romiti GF, Mei DA, et al. Efficacy of the ABC pathway for integrated care across phenotypes of patients with atrial fibrillation: a latent-class analysis report from the mAFA-II clinical trial. J Gen Intern Med. 2024. https:\/\/doi.org\/10.1007\/s11606-024-09037-6.","journal-title":"J Gen Intern Med"}],"container-title":["GeroScience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11357-025-02026-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11357-025-02026-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11357-025-02026-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T18:02:40Z","timestamp":1790186560000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11357-025-02026-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,4]]},"references-count":52,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["2026"],"URL":"https:\/\/doi.org\/10.1007\/s11357-025-02026-5","relation":{},"ISSN":["2509-2723"],"issn-type":[{"value":"2509-2723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,4]]},"assertion":[{"value":"20 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"For the EURObservational Research Programme (EORP) Atrial Fibrillation General Long-Term Registry, ethical approval was obtained at both national and institutional levels, and the study complied with the Declaration of Helsinki and EU guidelines for Good Clinical Practice (CPMP\/ECH\/135\/95). For the Asia\u2013Pacific Heart Rhythm Society (APHRS) AF registry, the respective local ethics committees approved the study protocol.","order":1,"name":"Ethics","label":"Ethics and consent to participate declarations","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"GFR reports consultancy for Boehringer Ingelheim and an educational grant from Anthos, outside the submitted work. No fees are directly received personally. GB is the Principal Investigator of the ARISTOTELES project (Applying.Artificial Intelligence to define clinical trajectories for personalized prediction and early detection of comorbidity and multimorbidity patterns that received funding from the European Union within the Horizon 2020 research and innovation program (Grant N. 101080189) and reports small speaker fees from Bayer, Boehringer Ingelheim, Boston, BMS, Daiichi, Sanofi, and Janssen outside the submitted work.GYHL: Consultant and speaker for BMS\/Pfizer, Boehringer Ingelheim, Daiichi-Sankyo, Anthos. No fees are received personally. He is a National Institute for Health and Care Research (NIHR) Senior Investigator and co-PI of the AFFIRMO project on multimorbidity in AF (grant agreement No 899871), TARGET project on digital twins for personalised management of atrial fibrillation and stroke (grant agreement No 101136244), and ARISTOTELES project on artificial intelligence for the management of chronic long-term conditions (grant agreement No 101080189), which are all funded by the EU\u2019s Horizon Europe Research and Innovation programme.MP: Italian national Principal Investigator of the AFFIRMO project on multimorbidity in atrial fibrillation, which has received funding from the European Union\u2019s Horizon 2020 research and innovation program under grant agreement No 899871.The other authors do not have conflicts of interest to report.","order":2,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}